Suven Life Sciences Limited — financial distress indicators
Financial-health summary
Suven Life Sciences Limited's reported numbers place it in the 'Weak' financial-health band (distress score 51/100). The main indicators are losses in each of the last 3 years, operations consume cash and ohlson o-score signals likely failure. Independently, the Ohlson accounting model puts its 1-year failure probability at 100% and the market-implied (Merton) default probability is 0.0%. In its favour: cash on hand covers all debt (net-cash balance sheet).
Stress by dimension
Share price — last 12 months
Indicators behind the score
Each red flag shows the evidence from the company’s own filings and the financial or legal principle behind it. Points add to the 0–100 score.
Net income negative in 3 of 3 fiscal years.
Persistent losses erode equity and the capacity to absorb shocks.
Operating cash flow negative in 3 of the last 3 years.
A business that cannot fund itself from operations depends on external capital to survive.
O-score 15.07 → model probability 100%.
Ohlson (1980) logit model of 1-year corporate failure; O > 0 (p > 50%) is the original failure cut-off.
Cash covers ~20 months of free-cash-flow burn.
Funding needs within two years make the company dependent on capital-market access.
Share count up +21% in a year.
Large issuance usually funds operating losses rather than growth.
Operating margin fell from -1149% to -4072% in two years.
Sharp margin compression signals loss of pricing power or cost control.
Revenue vs net income
Cash generation
Debt vs cash vs equity
✅ Mitigating factors
- Cash on hand covers all debt (net-cash balance sheet).
- Strong current ratio (29.15).
- High insider/promoter ownership (67%) aligns management with survival.
📰 Recent news scan
- Cohance Lifesciences (BSE:543064) Stock Forecast & Analyst Predictions - Simply Wall StreetGoogle News · 2026-10-05
- SUVEN.NS Q2 2026 Earnings: ₹12.13 Per-Share Loss as CNS-Focused Pharma Posts ₹7.11 Crore Revenue, Stock Slips 4.09% - Margin Expansion Trends - https://www.siam.in/Google News · 2026-10-02
- Suven Life Sciences Share Price update after sharp decline - UnivestGoogle News · 2026-10-01
- Suven Life Sciences Shares Decline Over 5% As Q1 Net Loss Widens To Rs 128 Crore - NDTV ProfitGoogle News · 2026-08-06
- Suven Life Plans Neuroscience Breakthrough by 2026-27 and Singapore Expansion - SahiGoogle News · 2026-07-20
- Market Trading Guide: Suven Life Sciences among 2 stock recommendations for Friday - The Economic TimesGoogle News · 2026-07-02
⚖️ Indian legal pathway — the IBC, 2016
How insolvency starts
- A financial creditor (§7), an operational creditor after a demand notice (§§8–9) or the company itself (§10) can apply to the NCLT once a default of at least ₹1 crore occurs (§4).
- On admission a moratorium (§14) stops suits and recovery; the board is suspended and an insolvency professional runs the company.
- The Committee of Creditors approves a resolution plan with 66% of voting share (§30(4)) within an outer limit of 330 days (§12); otherwise liquidation (§33) under the §53 waterfall — equity ranks last. Defaulting promoters are generally barred from bidding (§29A).
Earlier warning stages
- RBI's Prudential Framework for Resolution of Stressed Assets (7 June 2019): lenders must review a borrower within 30 days of default and implement a resolution plan, or provide more.
- Listed companies must disclose loan defaults to exchanges under SEBI (LODR); a rating downgrade to “D” is a public signal.
- Auditors must report going-concern uncertainty (SA 570 / Ind AS 1).
Frequently asked questions
What do Suven Life Sciences Limited's financial-health indicators show?
As of 2026-10-09, Suven Life Sciences Limited's public financial data places it in the 'Weak' band with a distress score of 51/100, driven by losses in each of the last 3 years, operations consume cash and ohlson o-score signals likely failure. This is a statistical screen of reported numbers — it does not mean the company is insolvent, has defaulted or will enter insolvency proceedings.
What is Suven Life Sciences Limited's financial distress score?
51/100 ('Weak'). Ohlson O-score 15.07 (model 1-year failure probability 100%). Merton distance-to-default 12.72 σ (model default probability 0.0%).
What works in Suven Life Sciences Limited's favour?
Cash on hand covers all debt (net-cash balance sheet). Strong current ratio (29.15). High insider/promoter ownership (67%) aligns management with survival.
How are shareholders treated if a company enters insolvency?
Under the IBC the Committee of Creditors controls the resolution; the §53 waterfall pays secured creditors and workers first and equity last. In most resolution plans existing shareholders are wiped out or left with a token stake, and the company may be delisted.
Other Pharma & Biotech companies with distress indicators
- Krebs Biochemicals & Industries Limited (KREBSBIO)Very weak 100/100
- Vivimed Labs Limited (VIVIMEDLAB)Very weak 100/100
- Mangalam Drugs & Organics Limited (MANGALAM)Very weak 90/100
- Lasa Supergenerics Limited (LASA)Very weak 82/100
- Ortin Global Limited (ORTINGLOBE)Very weak 77/100
- Zota Health Care Limited (ZOTA)Very weak 72/100
Methodology
Score = capped sum of rule-based red flags across seven dimensions (liquidity, solvency, profitability, cash flow, sales trend, market signal, news). Ohlson O-score (1980) gives an accounting-based 1-year failure probability; Merton distance-to-default (Bharath & Shumway 2008) gives a market-implied probability. Financial institutions use a capital-based rule set. Recalculated every trading day from the latest filings, prices and news.